A groundbreaking new blood test has the potential to transform the way postmenopausal women in England are diagnosed for womb cancer, sparing thousands from painful invasive procedures. Currently being trialled across several NHS hospitals, this innovative AI-powered test could significantly reduce the number of women who need to undergo uncomfortable transvaginal ultrasounds, a common diagnostic tool for suspected cases of cancer.
Addressing a Pressing Need
Every year, approximately 90,000 postmenopausal women in England are referred by their GPs for further investigation due to heavy bleeding, a symptom often associated with womb cancer. Of these, around 10,000 are diagnosed with the disease, also known as endometrial cancer, which sadly claims the lives of about 2,700 women annually.
The introduction of the PinPoint blood test could revolutionise this process by allowing healthcare providers to identify those who are at low risk of cancer, potentially eliminating the need for invasive procedures for up to 18,000 women each year. This is particularly significant, as currently, 20% of women referred for further testing do not actually have cancer but must still undergo uncomfortable examinations.
The Trial and Its Promising Results
The PinPoint test has already undergone extensive trials involving 16,481 patients referred from 170 GP practices in Yorkshire. Among the participants, 3,313 women were specifically referred due to concerns about womb cancer. The results have been impressive, with the test achieving a remarkable 99% accuracy rate in both detecting gynaecological cancers and ruling them out. This far surpasses the effectiveness of traditional diagnostic methods.
Due to these encouraging findings, both the Mid Yorkshire NHS Teaching Trust and Leeds Teaching Hospitals NHS Trust are planning to implement the test for various forms of gynaecological and upper gastrointestinal cancers.
The Science Behind the Test
Developed by Leeds-based PinPoint Data Science, the test employs advanced machine learning techniques to analyse 30 different blood markers, determining whether an individual is at low, elevated, or high risk of cancer. Prof Sean Duffy, the chief medical officer at PinPoint, emphasised the significance of the test’s accuracy, stating, “It is remarkable by any clinical standards.” He highlighted that the true value of the test lies in its ability to safely rule out women at very low risk of cancer, thereby eliminating unnecessary procedures.
Dr Jacinta Walsh, a GP from West Yorkshire, noted the often lengthy and stressful journey patients face before receiving a clear diagnosis. “It often takes up to six visits to a GP before we’re able to rule out cancer. PinPoint will help shortcut that process to deliver peace of mind earlier and free up our capacity to see other patients,” she remarked.
A Shift in Cancer Care
The implications of the PinPoint test extend beyond individual patients. Brent Kilmurray, chief executive of Mid Yorkshire NHS Trust, remarked on the compelling case for adopting this test. Tracy Jackson, a consultant gynaecologist at the Leeds Trust, echoed this sentiment, explaining that many women referred for scans do not have cancer, and the existing procedures can often be distressing.
“The Pinpoint test gives us a way to triage more intelligently. If we can confidently rule out low-risk women in primary care, we reduce unnecessary invasive procedures and shorten our waiting lists,” she said. This approach not only enhances patient care but also streamlines resources, allowing healthcare providers to focus more on those who need urgent attention.
Cancer Research UK has described the PinPoint test as “promising.” According to spokesperson Samantha Harrison, “Spotting cancer early saves lives, but right now patients are not being diagnosed quickly enough. This test could help to rule out endometrial cancer in some women, through a simple blood test, without the need for further testing.”
Why it Matters
The introduction of the PinPoint blood test heralds a new era in women’s health, offering a compassionate solution to a distressing issue. By alleviating the burden of invasive procedures for many women, this test not only enhances the quality of care but also empowers patients with timely and accurate information about their health. As more research unfolds, the hope is that this innovation will lead to earlier diagnoses, ultimately saving lives and reducing the emotional and physical toll associated with cancer investigations.
